Cyclosporin A: Ein Überblick über Anwendung, Wirksamkeit und Sicherheit bei Hunden

M. Linek; J. Linek; S. Kaps; L. Mecklenburg

doi:10.1055/s-0038-1622635

Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, Table of Contents

Tierarztl Prax Ausg K Kleintiere Heimtiere 2007; 35(05): 333-343
DOI: 10.1055/s-0038-1622635

Hund/Katze

Schattauer GmbH

Cyclosporin A: Ein Überblick über Anwendung, Wirksamkeit und Sicherheit bei Hunden

Cyclosporin A: A review of the application, efficacy and safety in dogs

Authors

M. Linek

¹Abteilung Dermatologie, Tierärztliche Spezialisten, Hamburg
J. Linek

²Abteilung Ophthalmologie, Tierärztliche Spezialisten, Hamburg
S. Kaps

²Abteilung Ophthalmologie, Tierärztliche Spezialisten, Hamburg
L. Mecklenburg

³Abteilung Pathologie, Tierärztliche Spezialisten, Hamburg

Abstract

Zusammenfassung:

Gegenstand und Ziel: Das Immunmodulativum Cyclosporin A (CsA) wird beim Hund in zunehmendem Maße zur Therapie von Erkrankungen der Haut und des Auges eingesetzt. Da es jedoch nur wenige plazebokontrollierte Studien zur Wirksamkeit gibt, treten bei Tierärzten und Tierbesitzern häufig Fragen zur Effektivität und Sicherheit von CsA auf. Material und Methoden: Diese Übersichtsarbeit fasst alle gegenwärtigen Anwendungsgebiete von CsA beim Hund zusammen, erläutert die in klinischen Studien nachgewiesene Wirksamkeit und diskutiert das Risikopotenzial von unerwünschten Nebenwirkungen. Ergebnisse: CsA-Formulierungen für Hunde sind in Deutschland für die Therapie der atopischen Dermatitis (AD) und der Keratoconjunctivitis sicca (KCS) zugelassen. Die Wirksamkeit wurde darüber hinaus bei perianalen Fisteln nachgewiesen. Bei Sebadenitis, steriler nodulärer Pannikulitis, Keratitis superficialis und lymphoplasmazellulärer Konjunktivitis liegen erste Daten zur Wirksamkeit von CsA vor. Sowohl die orale als auch die topische Applikation am Auge haben ein sehr begrenztes Spektrum an Nebenwirkungen. Schlussfolgerung: Beim Hund ist CsA ein effektives und bei kurzzeitiger Anwendung weitestgehend sicheres Therapeutikum bei einer Vielzahl immunologischer Erkrankungen. Die Effektivität in einigen Indikationsgebieten muss jedoch durch größere klinische Studien belegt werden. Daten zur Sicherheit bei Langzeitanwendung sind spärlich. Klinische Relevanz: Bei AD und KCS kann CsA problemlos gemäß der Anwendungshinweise eingesetzt werden. Bei einigen anderen Ekrankungen ist sein Einsatz von Fall zu Fall in Erwägung zu ziehen, weil es inzwischen viele Daten zur Effektivität und Sicherheit von CsA gibt.

Summary:

Objective: The immunomodulatory drug Cyclosporin A (CsA) is increasingly used in dogs to treat diseases of the skin and eye. Since placebo-controlled studies are rare, veterinarians and pet owners are frequently concerned about its efficacy and safety. Material and methods: This review summarizes all applications of CsA in dogs and discusses its efficacy and safety, as shown in clinical studies. Results: In Germany, CsAformulations for dogs are registered for the therapy of atopic dermatitis (AD) und keratoconjunctivitis sicca (KCS). In addition, efficacy has been proven in perianal fistulas. There is some data suggesting efficacy in sebaceous adenitis, sterile nodular panniculitis, superficial keratitis, and lymphoplasmacytic conjunctivitis. Both oral and topical ocular treatment have very few side effects. Conclusion: CsA is an effective and safe treatment of several immunologic diseases in dogs. In many indications, however, its efficacy needs to be verified in large clinical trials, and data on safety for long-term administration is still sparse. Clinical relevance: CsA can routinely be used in the treatment of canine AD and KCS. In some other diseases, its application may be indicated on a case-by-case decision, as there is evidence suggesting its efficacy and good tolerability.

Schlüsselwörter:

Cyclosporin A - Hund - Atopie - Keratoconjunctivitis sicca - Nebenwirkungen

Key words:

Cyclosporin A - dog - atopy - keratoconjunctivitis sicca - side effects

Full Text

References

Literatur
1 Abbas AK, Lichtmann A.H. The Immune System in Disease. In: Cellular and Molecular Immunology. 5th ed. Abbas AK, Lichtmann AH. eds Philadelphia: Saunders; 2003: 367-477
2 Aicher L, Wahl D, Arce A, Grenet O, Steiner S. New insights into cyclosporine. A nephrotoxicity by proteome analysis. Electrophoresis 1998; 19 (11) 1998-2003.
3 Amatori FM, Meucci V, Giusiani M, Soldani G, Corazza M, Giorgi M. Effect of grapefruit juice on the pharmacokinetics of cyclosporine in dogs. Vet Rec 2004; 154 (06) 180-181.
4 Barth T, Mischke R, Nolte I. Cyclosporin A in aplastic anemia in dogs: first results. Berl Münch Tierärztl Wochenschr 1997; 110 (02) 60-67.
5 BenEzra D, Maftzir G. Ocular penetration of Cyclosporin A. The rabbit eye. Invest Ophthalmol Vis Sci 1990; 31 (07) 1362-1366.
6 BenEzra D, Maftzir G de Court, Timonen P. Ocular penetration of Cyclosporin A. III: The human eye. Br J Ophthalmol 1990; 74 (06) 350-352.
7 Bensignor EGE. Utilisation de la ciclosporine pour le traitement des formes rebelles de dermatite atopique canine (use of cyclosporin for treatment of refractory canine atopic dermatitis). Pratique-Medicale-and-Chirurgicalede- l'Animal-de-Compagnie 2004; 39: 15-19.
8 Bernsteen L, Gregory CR, Kyles AE, Griffey SM, Patz J. Microemulsified cyclosporine-based immunosuppression for the prevention of acute renal allograft rejection in unrelated dogs: preliminary experimental study. Vet Surg 2003; 32 (03) 213-219.
9 Breathnach RM, Baker KP, Quinn PJ, McGeady TA, Aherne CM, Jones BR. Clinical, immunological and histopathological findings in a subpopulation of dogs with pododermatitis. Vet Dermatol 2005; 16 (06) 364-372.
10 Burton G, Burrows A, Walker R, Robson D, Bassett R, Bryden S. et al Efficacy of cyclosporin in the treatment of atopic dermatitis in dogs – combined results from two veterinary dermatology referral centres. Aust Vet J 2004; 82 (11) 681-685.
11 Callan MB, Preziosi D, Mauldin E. Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine. Vet Dermatol 2005; 16 (05) 338-345.
12 Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 1996; 30 (02) 141-179.
13 Carothers MA, Kwochka KW, Rojko JL. Cyclosporine-responsive granulomatous sebaceous adenitis in a dog. J Am Vet Med Assoc 1991; 198 (09) 1645-1648.
14 Clarke K, MacCall C, Steffan J. The effects of cyclosporine A and oral prednisolon on flea allergen specific serum IgE and intradermal tests in experimentally sensitized laboratory beagles. Proceedings of the 1st European Society of Veterinary Dermatology/European College Veterinary Dermatology Nice. 2002: 223
15 Dahlinger J, Gregory C, Bea J. Effect of ketoconazole on cyclosporine dose in healthy dogs. Vet Surg 1998; 27 (01) 64-68.
16 Daigle JC, Hosgood G, Foil CS, Hunter RP. Effect of cimetidine on pharmacokinetics of orally administered cyclosporine in healthy dogs. Am J Vet Res 2001; 62 (07) 1046-1050.
17 Doust R, Griffiths LG, Sullivan M. Evaluation of once daily treatment with cyclosporine for anal furunculosis in dogs. Vet Rec 2003; 152 (08) 225-229.
18 Dupuy P, Bagot M, Michel L, Descourt B, Dubertret L. Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro. J Invest Dermatol 1991; 96 (04) 408-413.
19 Favrot C, Olivry T, Werner AH, Nespecca G, Utiger A, Grest P. et al Evaluation of papillomaviruses associated with cyclosporine-induced hyperplastic verrucous lesions in dogs. Am J Vet Res 2005; 66 (10) 1764-1769.
20 Fontaine J, Olivry T. Treatment of canine atopic dermatitis with cyclosporine: a pilot clinical study. Vet Rec 2001; 148 (21) 662-663.
21 Ford J, Woolfe J, Florence AT. Nanospheres of Cyclosporin A: poor oral absorption in dogs. Int J Pharm 1999; 183 (01) 3-6.
22 Fullard RJ, Kaswan RM, Bounous DI, Hirsh SG. Tear protein profiles vs clinical characteristics of untreated and cyclosporine-treated canine KC. J Am Optom Assoc 1995; 66 (07) 397-404.
23 Furue M, Gaspari AA, Katz SI. The effect of Cyclosporin A on epidermal cells. II. Cyclosporin A inhibits proliferation of normal and transformed keratinocytes. J Invest Dermatol 1988; 90 (06) 796-800.
24 Garcia dM, O’Valle F, Andujar M, Aguilar M, Lucena MA, Lopez-Hidalgo J. et al Relationship between P-glycoprotein expression and Cyclosporin A in kidney. An immunohistological and cell culture study. Am J Pathol 1995; 146 (02) 398-408.
25 Guaguere E. Efficacy of cyclosporine in the treatment of idiopathic sterile nodular panniculitis in two dogs. Vet Dermatol 2000; 11: 20
26 Guaguere E, Steffan J, Olivry T. Cyclosporin A: a new drug in the field of canine dermatology. Vet Dermatol 2004; 15 (02) 61-74.
27 Hall JA, Waigalls SE, Mathiews KA. Oral cyclosporine in the treatment of end stae ear disease: a pilot study. Proceedings of 18th Annual Meeting of the American Academy of Veterinary Dermatology/American College of Veterinary Dermatology Monterey. 2003: 217
28 Hardie RJ, Gregory SP, Tomlin J, Sturgeon C, Lipscomb V, Ladlow J. Cyclosporine treatment of anal furunculosis in 26 dogs. J Small Anim Pract 2005; 46 (01) 3-9.
29 Hess AD. Mechanisms of action of cyclosporine: considerations for the treatment of autoimmune diseases. Clin Immunol Immunopathol 1993; 68 (02) 220-228.
30 Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D. et al The mechanism of action of Cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80 (3 Pt 2) S40-S45.
31 Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T. et al Effects of grapefruit juice and orange juice components on P-glycoproteinand MRP2-mediated drug efflux. Br J Pharmacol 2004; 143 (07) 856-864.
32 Ito F, Toyota N, Sakai H, Takahashi H, Iizuka H. FK506 and Cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. Arch Dermatol Res 1999; 291 (05) 275-283.
33 Kaswan RL. Characteristics of a canine model of KCS: effective treatment with topical cyclosporine. Adv Exp Med Biol 1994; 350: 583-594.
34 Kaswan RL. Intraocular penetration of topically applied cyclosporin. Transplant Proc 1988; 20 2 Suppl (Suppl. 02) 650-655.
35 Kaswan RL, Kaplan HJ, Martin CL. Topically applied cyclosporin for modulation of induced immunogenic uveitis in rabbits. Am J Vet Res 1988; 49 (10) 1757-1759.
36 Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine. Vet Clin North Am Small Anim Pract 1990; 20 (03) 583-613.
37 Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol 1989; 107 (08) 1210-1216.
38 Korthäuer W. Topische und dermatologische Anwendung von Cyclosporin A außerhalb des Auges: erste Ergebnisse. Kleintierprax 1999; (01) 24-25.
39 Linek J. Cyclosporine in the perioperative phase of cataract surgery in the dog. Proceedings of the International Veterinary Opthalmology Meeting ECVO-ESVO-DOK, Munich. 2004: 97-98
40 Linek M, Boss C, Haemmerling R, Hewicker-Trautwein M, Mecklenburg L. Effects of cyclosporine A on clinical and histologic abnormalities in dogs with sebaceous adenitis. J Am Vet Med Assoc 2005; 226 (01) 59-64.
41 Mathews KA, Ayres SA, Tano CA, Riley SM, Sukhiani HR, Adams C. Cyclosporin treatment of perianal fistulas in dogs. Can Vet J 1997; 38 (01) 39-41.
42 Mathews KA, Holmberg DL, Miller CW. Kidney transplantation in dogs with naturally occurring end-stage renal disease. J Am Anim Hosp Assoc 2000; 36 (04) 294-301.
43 Mathews KA, Sukhiani HR. Randomized controlled trial of cyclosporine for treatment of perianal fistulas in dogs. J Am Vet Med Assoc 1997; 211 (10) 1249-1253.
44 Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47 2–3 119-125.
45 Maurer M, Handjiski B, Paus R. Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Am J Pathol 1997; 150 (04) 1433-1441.
46 Moore CP, McHugh JB, Thorne JG, Phillips TE. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Invest Ophthalmol Vis Sci 2001; 42 (03) 653-659.
47 Morton RS, Dongari-Bagtzoglou AI. Regulation of gingival fibroblast interleukin- 6 secretion by cyclosporine A. J Periodontol 1999; 70 (12) 1464-1471.
48 Mouatt JG. Cyclosporin and ketoconazole interaction for treatment of perianal fistulas in the dog. Aust Vet J 2002; 80 (04) 207-211.
49 Myre SA, Schoeder TJ, Grund VR, Wandstrat TL, Nicely PG, Pesce AJ. et al Critical ketoconazole dosage range for ciclosporin clearance inhibition in the dog. Pharmacology 1991; 43 (05) 233-241.
50 Nemeth T, Toth J, Balogh L, Janoki G, Manczur F, Voros K. et al Principles of renal transplantation in the dog: A review. Acta Vet Hung 1997; 45 (02) 213-226.
51 Noli C, Toma S. Three cases of immune-mediated adnexal skin disease treated with cyclosporin. Vet Dermatol 2006; 17 (01) 85-92.
52 O‘Neil MJ. Cyclosporin. In O‘Neil MJ, Smith A, Heckelman PE. eds The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals. Whitehouse Station: Merck Research Laboratories; 2002
53 Olivero DK, Davidson MG, English RV, Nasisse MP, Jamieson VE, Gerig TM. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. JAm Vet MedAssoc 1991; 199 (08) 1039-1042.
54 Olivry T, Rivierre C, Jackson HA, Murphy KM, Davidson G, Sousa CA. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Vet Dermatol 2002; 13 (02) 77-87.
55 Olivry T, Rivierre C, Jackson HA, Murphy KM, Davidson G, Sousa CA. Maintenance treatment of canine atopic dermatitis with cyclosporin: decreasing dosages or increasing intervals? (Abstract). Vet Dermatol 2003; 14: 210
56 Olivry T, Rivierre C, Murphy KM. Efficacy of cyclosporine for treatment induction of canine pemphigus foliaceus. Vet Rec 2003; 152 (02) 53-54.
57 Olivry T, Steffan J, Fisch RD, Prelaud P, Guaguere E, Fontaine J. et al Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2002; 221 (03) 370-377.
58 Ouisuwan S, Buranakarl C. Effects of Cyclosporin A on blood pressure, baroreceptor reflex and renal function in dogs. Vet Res Commun 2005; 29 (03) 201-213.
59 Paterson S. Successful therapy of sebaceous adenitis with topical cyclosporine in 20 dogs. Vet Dermatol 2004; 15 Supplement (Suppl. 01) 64
60 Patricelli AJ, Hardie RJ, McAnulty JE. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. J Am Vet Med Assoc 2002; 220 (07) 1009-1016.
61 Paus R, Stenn KS, Link RE. The induction of anagen hair growth in telogen mouse skin by cyclosporine A administration. Lab Invest 1989; 60 (03) 365-369.
62 Petri JB, Schurk S, Gebauer S, Haustein UF. Cyclosporine A delays wound healing and apoptosis and suppresses activin beta-A expression in rats. Eur J Dermatol 1998; 8 (02) 104-113.
63 Quesniaux VF. Pharmacology of cyclosporine (sandimmune). III. Immunochemistry and monitoring. Pharmacol Rev 1990; 41 (03) 249-258.
64 Radowicz SN, Power HT. Long-term use of cyclosporine in the treatment of canine atopic dermatitis. Vet Dermatol 2005; 16 (02) 81-86.
65 Read RA. Cyclosporin and its treatment of ophthalmic diseases in animals. Aust Vet Practit 1996; 26: 86-91.
66 Read RA. Treatment of canine nictitans plasmacytic conjunctivitis with 0.2 per cent cyclosporin ointment. J Small Anim Pract 1995; 36 (02) 50-56.
67 Ritschel WA. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clin Transplant 1996; 10 (04) 364-373.
68 Robson D. Review of the properties and mechanisms of action of cyclosporine with an emphasis on dermatological therapy in dogs, cats and people. Vet Rec 2003; 152 (25) 768-772.
69 Robson DC, Burton GG. Cyclosporin: applications in small animal dermatology. Vet Dermatol 2003; 14 (01) 1-9.
70 Rosenkrantz WS. Pemphigus: current therapy. Vet Dermatol 2004; 15 (02) 90-98.
71 Rosenkrantz WS, Griffin CE, Barr RJ, Biren CA. Cyclosporine and cutaneous immune-mediated disease. J Am Acad Dermatol 1986; 14 (06) 1088-1089.
72 Rosser EJ. Therapy of sebaceous adenitis. In: Kirk’s Current Veterinary Therapy XIII. Bonagura JD, Kirk DW. eds Philadelphia: Saunders; 2000: 572-573
73 Rybnicek J, Affolter VK, Moore PF. Sebaceous adenitis: an immunohistological examination. In: Advances in Veterinary Dermatology, Vol. 3. Kwochka KW, Willemse T, von Tscharner C. eds. Oxford: Butterworth Heinemann; 2006: 539
74 Ryffel B. Experimental toxicological studies with cyclosporine. In Cyclosporine A, White DJG. ed Amsterdam: Elsevier Biomedical Press; 1982: 45-75
75 Salisbury MA, Kaswan RL, Brown J. Microorganisms isolated from the corneal surface before and during topical cyclosporine treatment in dogs with keratoconjunctivitis sicca. Am J Vet Res 1995; 56 (07) 880-884.
76 Sansom J, Barnett KC, Neumann W, Schulte-Neumann A, Clerc B, Jegou JP. et al Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial. Vet Rec 1995; 137 (20) 504-507.
77 Seibel W, Yahia NA, McCleary LB, Lesko LJ, Hassell TM. Cyclosporine-induced gingival overgrowth in beagle dogs. J Oral Pathol Med 1989; 18 (04) 240-245.
78 Steffan J, Alexander D, Brovedani F, Fisch RD. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Vet Dermatol 2003; 14 (01) 11-22.
79 Steffan J, Favrot C, Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006; 17 (01) 3-16.
80 Steffan J, Horn J, Gruet P, Strehlau G, Fondati A, Ferrer L. et al Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with Cyclosporin A or methylprednisolone. Vet Rec 2004; 154 (22) 681-684.
81 Steffan J, Parks C, Seewald W. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. J Am Vet Med Assoc 2005; 226 (11) 1855-1863.
82 Steffan J, Strehlau G, Maurer M, Rohlfs A. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther 2004; 27 (04) 231-238.
83 Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet 2005; 44 (03) 247-261.
84 Thelen A, Mueller RS, Linek M, Peters S, Stechmann K, Steffan J. The influence of food intake on the clinical response to Cyclosporin A in canine atopic dermatitis. Vet Rec (in press). nnn.
85 Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87 (11) 1322-1330.
86 Wahlstrom HE, Lavelle-Jones M, Endres D, Akimoto R, Kolterman O, Moossa AR. Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog. Transplantation 1990; 49 (03) 600-604.
87 Wakefield D, McCluskey P, Reece G. Cyclosporin therapy in Vogt Koyanagi Harada disease. Aust N Z J Ophthalmol 1990; 18 (02) 137-142.
88 Whalen RD, Tata PN, Burckart GJ, Venkataramanan R. Species differences in the hepatic and intestinal metabolism of cyclosporine. Xenobiotica 1999; 29 (01) 3-9.
89 Willemse A, van den Brom WE. Investigations of the symptomatology and the significance of immediate skin test reactivity in canine atopic dermatitis. Res Vet Sci 1983; 34 (03) 261-265.
90 Williams DL, Hoey AJ, Smitherman P. Comparison of topical Cyclosporin and dexamethasone for the treatment of chronic superficial keratitis in dogs. Vet Rec 1995; 137 (25) 635-639.
91 Wong RL, Winslow CM, Cooper KD. The mechanisms of action of Cyclosporin A in the treatment of psoriasis. Immunol Today 1993; 14 (02) 69-74.